StockData
Anavex Life Sciences Corp. logo

Anavex Life Sciences Corp. (AVXL) stock

AVXLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 28, 2026Score 6/30
$0.67−0.05 (-7.21%)

Close on Nov 19, 2026Market cap $61.88MP/E –Yield –

Anavex Life Sciences operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Anavex Life Sciences's operating income for the twelve months ending Jun 30, 2026 was -$17.37M. For fiscal 2025 it was -$51.41M. The highest annual figure on record is -$2.14M in fiscal 2013.

Annual operating income

PeriodPeriod endValueChange
FY2025Sep 30, 2025-$51.41M–
FY2024Sep 30, 2024-$52.88M–
FY2023Sep 30, 2023-$55.76M–
FY2022Sep 30, 2022-$50.99M–
FY2021Sep 30, 2021-$42.00M–
FY2020Sep 30, 2020-$31.09M–
FY2014Sep 30, 2014-$2.97M–
FY2013Sep 30, 2013-$2.14M–
FY2012Sep 30, 2012-$4.32M–
FY2011Sep 30, 2011-$6.18M–
FY2010Sep 30, 2010-$5.65M–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2026CQ2 2026Jun 30, 2026$6.74M–
Q2 FY2026CQ1 2026Mar 31, 2026-$6.48M–
Q1 FY2026CQ4 2025Dec 31, 2025-$6.78M–
Q4 FY2025CQ3 2025Sep 30, 2025-$10.84M–
Q3 FY2025CQ2 2025Jun 30, 2025-$14.46M–
Q2 FY2025CQ1 2025Mar 31, 2025-$12.51M–
Q1 FY2025CQ4 2024Dec 31, 2024-$13.59M–
Q4 FY2024CQ3 2024Sep 30, 2024-$14.27M–
Q3 FY2024CQ2 2024Jun 30, 2024-$14.60M–
Q2 FY2024CQ1 2024Mar 31, 2024-$12.62M–
Q1 FY2024CQ4 2023Dec 31, 2023-$11.38M–
Q4 FY2023CQ3 2023Sep 30, 2023-$12.66M–
Q3 FY2023CQ2 2023Jun 30, 2023-$13.53M–
Q2 FY2023CQ1 2023Mar 31, 2023-$14.19M–
Q1 FY2023CQ4 2022Dec 31, 2022-$15.38M–
Q4 FY2022CQ3 2022Sep 30, 2022-$15.28M–
Q3 FY2022CQ2 2022Jun 30, 2022-$12.46M–
Q2 FY2022CQ1 2022Mar 31, 2022-$11.52M–
Q1 FY2022CQ4 2021Dec 31, 2021-$11.72M–

More Anavex Life Sciences figures

See a number that looks wrong?